Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2

In this Phase III study (n=1072), the humanized anti–CGRP monoclonal antibody eptinezumab was associated with a larger reduction in mean monthly migraine days over 12 weeks than placebo (placebo −5.6, 100mg −7.7, p<0.0001 vs placebo; 300mg −8.2, p<0.0001 vs placebo).

SPS commentary:

Eptinezumab is approved in the US but not yet approved in the EU/UK.